Monoclonal antibodies that target PD-1 or PD-L1 often referred to as checkpoint inhibitors are used to treat various cancers, including melanoma [14], non-small cell lung cancer [15], kidney cancer, bladder cancer, head and neck cancers, and Hodgkin lymphoma. Here, CD274 is linked to melanoma.